TAT-NEP1-40 as a novel therapeutic candidate for axonal regeneration and functional recovery after stroke

References

• Atalay B, Bavbek M, Cekinmez M, Ozen O, Nacar A, Karabay G, Gulsen S. (2007). Antibodies neutralizing Nogo-A increase pan-cadherin expression and motor recovery following spinal cord injury in rats. Spinal Cord, 45, 780–786.
   PubMed Web of Science ®Google Scholar
• Atalay B, Bavbek M, Ozen O, Nacar A, Gülsen S, Yigitkanli K, Caner H, Altinörs N. (2008). Nogo-A inhibitory peptide (NEP1-40) increases pan-cadherin expression following mild cortical contusion injury in rats. Turk Neurosurg, 18, 356–365.
   PubMed Web of Science ®Google Scholar
• Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C, Tessier-Lavigne M. (2008). PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science, 322, 967–970.
   PubMed Web of Science ®Google Scholar
• Barton WA, Liu BP, Tzvetkova D, Jeffrey PD, Fournier AE, Sah D, Cate R, Strittmatter SM, Nikolov DB. (2003). Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J, 22, 3291–3302.
   PubMed Web of Science ®Google Scholar
• Becker-Hapak M, McAllister SS, Dowdy SF. (2001). TAT-mediated protein transduction into mammalian cells. Methods, 24, 247–256.
   PubMed Web of Science ®Google Scholar
• Cao Y, Shumsky JS, Sabol MA, Kushner RA, Strittmatter S, Hamers FP, Lee DH, Rabacchi SA, Murray M. (2008). Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat. Neurorehabil Neural Repair, 22, 262–278.
   PubMed Web of Science ®Google Scholar
• Cao Z, Gao Y, Deng K, Williams G, Doherty P, Walsh FS. (2010). Receptors for myelin inhibitors: structures and therapeutic opportunities. Mol Cell Neurosci, 43, 1–14.
   PubMed Web of Science ®Google Scholar
• Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ. (2007). The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J Neurosci, 27, 7117–7124.
   PubMed Web of Science ®Google Scholar
• Denicourt C, Dowdy SF. (2003). Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol Sci, 24, 216–218.
   PubMed Web of Science ®Google Scholar
• Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E, Kimura N, Cai H, Deng K, Gao Y, He Z, Filbin M. (2002). Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron, 35, 283–290.
   PubMed Web of Science ®Google Scholar
• Donnan GA, Fisher M, Macleod M, Davis SM. (2008). Stroke. Lancet, 371, 1612–1623.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Pehar M, Cassina P, Rene F, Castellanos R, Rouaux C, Gandelman M, Dimou L, Schwab ME, Loeffler JP, Barbeito L, Gonzalez de Aguilar JL. (2008). Nogo receptor antagonizes p75NTR-dependent motor neuron death. Proc Natl Acad Sci USA, 105, 740–745.
   PubMed Web of Science ®Google Scholar
• Edaravone Acute Infarction Study Group. (2003). Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 15, 222–229.
   PubMed Web of Science ®Google Scholar
• Egleton RD, Davis TP. (1997). Bioavailability and transport of peptides and peptide drugs into the brain. Peptides, 18, 1431–1439.
   PubMed Web of Science ®Google Scholar
• Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. (1994). Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA, 91, 664–668.
   PubMed Web of Science ®Google Scholar
• Feigin VL. (2005). Stroke epidemiology in the developing world. Lancet, 365, 2160–2161.
   PubMed Web of Science ®Google Scholar
• Filbin MT. (2003). Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci, 4, 703–713.
   PubMed Web of Science ®Google Scholar
• Filbin MT. (2008). PirB, a second receptor for the myelin inhibitors of axonal regeneration Nogo66, MAG, and OMgp: implications for regeneration in vivo. Neuron, 60, 740–742.
   PubMed Web of Science ®Google Scholar
• Fisher M, Bastan B. (2008). Treating acute ischemic stroke. Curr Opin Drug Discov Devel, 11, 626–632.
   PubMed Web of Science ®Google Scholar
• Fournier AE, Gould GC, Liu BP, Strittmatter SM. (2002). Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci, 22, 8876–8883.
   PubMed Web of Science ®Google Scholar
• Fournier AE, GrandPre T, Strittmatter SM. (2001). Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature, 409, 341–346.
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 55, 1189–1193.
   PubMed Web of Science ®Google Scholar
• Galvin R, Murphy B, Cusack T, Stokes E. (2008). The impact of increased duration of exercise therapy on functional recovery following stroke–what is the evidence? Top Stroke Rehabil, 15, 365–377.
   PubMed Web of Science ®Google Scholar
• GrandPré T, Li S, Strittmatter SM. (2002). Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature, 417, 547–551.
   PubMed Web of Science ®Google Scholar
• Green M, Loewenstein PM. (1988). Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell, 55, 1179–1188.
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med, 333, 1581–1587.
   PubMed Web of Science ®Google Scholar
• Guégan C, Braudeau J, Couriaud C, Dietz GP, Lacombe P, Bähr M, Nosten-Bertrand M, Onténiente B. (2006). PTD-XIAP protects against cerebral ischemia by anti-apoptotic and transcriptional regulatory mechanisms. Neurobiol Dis, 22, 177–186.
   PubMed Web of Science ®Google Scholar
• Guo F, Li SQ, Chu YH, Huang XF, Sun LM, Li YQ, Li HJ, Zhou TH. (2007). High-level expression, polyclonal antibody preparation and sub-cellular localization analysis of mouse Rhox5 protein. Protein Expr Purif, 54, 247–252.
   PubMed Web of Science ®Google Scholar
• Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E. (2009). Blockade of Nogo receptor ligands promotes functional regeneration of sensory axons after dorsal root crush. J Neurosci, 29, 6285–6295.
   PubMed Web of Science ®Google Scholar
• Hou S, Tian W, Xu Q, Cui F, Zhang J, Lu Q, Zhao C. (2006). The enhancement of cell adherence and inducement of neurite outgrowth of dorsal root ganglia co-cultured with hyaluronic acid hydrogels modified with Nogo-66 receptor antagonist in vitro. Neuroscience, 137, 519–529.
   Google Scholar
• Kastin AJ, Pan W. (2005). Targeting neurite growth inhibitors to induce CNS regeneration. Curr Pharm Des, 11, 1247–1253.
   PubMed Web of Science ®Google Scholar
• Kilic E, Kilic U, Hermann DM. (2006). TAT fusion proteins against ischemic stroke: current status and future perspectives. Front Biosci, 11, 1716–1721.
   PubMed Web of Science ®Google Scholar
• Kilic U, Kilic E, Dietz GP, Bähr M. (2003). Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke, 34, 1304–1310.
   PubMed Web of Science ®Google Scholar
• Kim DW, Eum WS, Jang SH, Kim SY, Choi HS, Choi SH, An JJ, Lee SH, Lee KS, Han K, Kang TC, Won MH, Kang JH, Kwon OS, Cho SW, Kim TY, Park J, Choi SY. (2005). Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol Cells, 19, 88–96.
   PubMed Web of Science ®Google Scholar
• Kim JE, Liu BP, Park JH, Strittmatter SM. (2004). Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron, 44, 439–451.
   PubMed Web of Science ®Google Scholar
• Lansberg MG, Schwartz NE. (2009). Tissue plasminogen activator does not benefit most eligible patients with stroke. Arch Neurol, 66, 540–541; author reply 541.
   PubMed Web of Science ®Google Scholar
• Laurén J, Airaksinen MS, Saarma M, Timmusk T. (2003). Two novel mammalian Nogo receptor homologs differentially expressed in the central and peripheral nervous systems. Mol Cell Neurosci, 24, 581–594.
   PubMed Web of Science ®Google Scholar
• Laurén J, Hu F, Chin J, Liao J, Airaksinen MS, Strittmatter SM. (2007). Characterization of myelin ligand complexes with neuronal Nogo-66 receptor family members. J Biol Chem, 282, 5715–5725.
   PubMed Web of Science ®Google Scholar
• Lee JK, Kim JE, Sivula M, Strittmatter SM. (2004). Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci, 24, 6209–6217.
   PubMed Web of Science ®Google Scholar
• Legg LA, Drummond AE, Langhorne P. (2006). Occupational therapy for patients with problems in activities of daily living after stroke. Cochrane Database Syst Rev, CD003585.
   PubMed Web of Science ®Google Scholar
• Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah DW, Pepinsky B, Lee D, Relton J, Strittmatter SM. (2004). Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci, 24, 10511–10520.
   PubMed Web of Science ®Google Scholar
• Li S, Strittmatter SM. (2003). Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci, 23, 4219–4227.
   PubMed Web of Science ®Google Scholar
• Liu BP, Fournier A, GrandPré T, Strittmatter SM. (2002). Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science, 297, 1190–1193.
   PubMed Web of Science ®Google Scholar
• McGee AW, Strittmatter SM. (2003). The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci, 26, 193–198.
   PubMed Web of Science ®Google Scholar
• Mehta NR, Lopez PH, Vyas AA, and Schnaar RL. (2007). Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells. J Biol Chem, 282, 27875–27886.
   PubMed Web of Science ®Google Scholar
• Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Sands B, Crowell T, Cate RL, McCoy JM, Pepinsky RB. (2004). LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci, 7, 221–228.
   PubMed Web of Science ®Google Scholar
• Mingorance A, Solé M, Munetón V, Martínez A, Nieto-Sampedro M, Soriano E, del Río JA. (2006). Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling. FASEB J, 20, 491–493.
   PubMed Web of Science ®Google Scholar
• Misra A, Ganesh S, Shahiwala A, Shah SP. (2003). Drug delivery to the central nervous system: a review. J Pharm Pharm Sci, 6, 252–273.
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Yamadate K, Kobayashi M, Endo H, Fukuda T, Yoshida K, Terasaki K, Inoue T, Ogawa A. (2005). Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy. Surg Neurol, 64, 309–313; discussion 313.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2, 3–14.
   PubMedGoogle Scholar
• Park JB, Yiu G, Kaneko S, Wang J, Chang J, He XL, Garcia KC, He Z. (2005). A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron, 45, 345–351.
   PubMed Web of Science ®Google Scholar
• Pignot V, Hein AE, Barske C, Wiessner C, Walmsley AR, Kaupmann K, Mayeur H, Sommer B, Mir AK, Frentzel S. (2003). Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor. J Neurochem, 85, 717–728.
   PubMed Web of Science ®Google Scholar
• Prinsloo E, Oosthuizen V, Muramoto K, Naude RJ. (2006). In vitro refolding of recombinant human free secretory component using equilibrium gradient dialysis. Protein Expr Purif, 47, 179–185.
   PubMed Web of Science ®Google Scholar
• Salter K, Hellings C, Foley N, Teasell R. (2008). The experience of living with stroke: a qualitative meta-synthesis. J Rehabil Med, 40, 595–602.
   PubMed Web of Science ®Google Scholar
• Saver JL. (2006). Time is brain–quantified. Stroke, 37, 263–266.
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569–1572.
   PubMed Web of Science ®Google Scholar
• Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V, Pepinsky RB, Mi S. (2005). TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron, 45, 353–359.
   PubMed Web of Science ®Google Scholar
• Steward O, Sharp K, Yee KM, Hofstadter M. (2008). A re-assessment of the effects of a Nogo-66 receptor antagonist on regenerative growth of axons and locomotor recovery after spinal cord injury in mice. Exp Neurol, 209, 446–468.
   PubMed Web of Science ®Google Scholar
• Szeder V, Torbey MT. (2008). Prevention and treatment of perioperative stroke. Neurologist, 14, 30–36.
   PubMed Web of Science ®Google Scholar
• Teng FY, Tang BL. (2005). Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents? J Neurochem, 94, 865–874.
   PubMed Web of Science ®Google Scholar
• Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, Ibayashi S, Iida M. (2004). Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci, 221, 11–17.
   PubMed Web of Science ®Google Scholar
• Uno M, Kitazato KT, Suzue A, Matsuzaki K, Harada M, Itabe H, Nagahiro S. (2005). Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radic Biol Med, 39, 1109–1116.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. (1998). Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target, 6, 151–165.
   PubMed Web of Science ®Google Scholar
• Venkatesh K, Chivatakarn O, Sheu SS, Giger RJ. (2007). Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. J Cell Biol, 177, 393–399.
   PubMed Web of Science ®Google Scholar
• Wang F, Liang Z, Hou Q, Xing S, Ling L, He M, Pei Z, Zeng J. (2007). Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. Neurosci Lett, 417, 255–260.
   PubMed Web of Science ®Google Scholar
• Wang KC, Kim JA, Sivasankaran R, Segal R, He Z. (2002a). P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature, 420, 74–78.
   PubMed Web of Science ®Google Scholar
• Wang Q, Gou X, Jin W, Xiong L, Hou L, Chen S, Zhang H, Zhu X, Xu L. (2009). TAT-mediated protein transduction of Nogo extracellular peptide 1-40 and its biological activity. Cell Mol Neurobiol, 29, 97–108.
   PubMed Web of Science ®Google Scholar
• Wang Q, Gou X, Xiong L, Jin W, Chen S, Hou L, Xu L. (2008). Trans-activator of transcription-mediated delivery of NEP1-40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via inhibition of neuronal apoptosis. Anesthesiology, 108, 1071–1080.
   PubMed Web of Science ®Google Scholar
• Wang X, Baughman KW, Basso DM, Strittmatter SM. (2006). Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Ann Neurol, 60, 540–549.
   PubMed Web of Science ®Google Scholar
• Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM. (2002b). Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci, 22, 5505–5515.
   PubMed Web of Science ®Google Scholar
• West C, Bowen A, Hesketh A, Vail A. (2008). Interventions for motor apraxia following stroke. Cochrane Database Syst Rev, CD004132.
   PubMed Web of Science ®Google Scholar
• Wong ST, Henley JR, Kanning KC, Huang KH, Bothwell M, Poo MM. (2002). A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat Neurosci, 5, 1302–1308.
   PubMed Web of Science ®Google Scholar
• Yepes M, Roussel BD, Ali C, Vivien D. (2009). Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci, 32, 48–55.
   PubMed Web of Science ®Google Scholar
• Yiu G, He Z. (2006). Glial inhibition of CNS axon regeneration. Nat Rev Neurosci, 7, 617–627.
   PubMed Web of Science ®Google Scholar
• Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC, Steward O, Tessier-Lavigne M. (2005). Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci USA, 102, 1205–1210.
   PubMed Web of Science ®Google Scholar